MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative

    M-L. Zeissler, N. Lapelle, S. Collins, E. Cowd, C. Gonzalez-Robles, R. Ellis-Doyle, G. Mills, R. Petty, T. Foltynie, C. Carroll, K. Mcfarthing (Plymouth, United Kingdom)

    Objective: To improve patient and public involvement and engagement (PPIE) within EJS ACT-PD by evaluating members’ perceptions of PPIE through a mixed methods research-in-action study.…
  • 2024 International Congress

    Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease

    R. Hauser, M. Bouchard, D. Santos-Garcia, L. Bergmann, R. Gupta, L. Harmer, M. Shah, C. Yan, S. Isaacson (Tampa, USA)

    Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…
  • 2024 International Congress

    Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants

    P. Agarwal, N. Crouse, A. Breiteneicher, M. Formella (Kirkland, USA)

    Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…
  • 2024 International Congress

    Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat

    W. Kang, Y. Kulkarni, I. Frouni, C. Kwan, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
  • 2024 International Congress

    Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease

    L. Ponsati, S. Hansen, M. Scharff, H. Klitgaard, S. Kauppinen, E. Bezard, J. Erler (København SV, Denmark)

    Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…
  • 2024 International Congress

    Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease

    XD. Yang, Q. Xiao, XQ. He (Shanghai, China)

    Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…
  • 2024 International Congress

    A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi

    M. Gwedela, T. Phiri (Blantyre, Malawi)

    Objective: The objective of the study is to analyze the clinical and socio-demographic characteristics of people with Parkinson`s (PwP) attending the adult neurology outpatient clinic…
  • 2024 International Congress

    Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa

    YR. Han, S. Stodtmann, M. Rosebraugh (North Chicago, USA)

    Objective: To characterize the pharmacokinetics (PK) of levodopa (LD) after bolus delivery of foslevodopa/foscarbidopa Background: Foslevodopa/foscarbidopa is a soluble formulation of LD/CD prodrugs delivered as…
  • 2024 International Congress

    Long term evaluation of gluten-free diet in Parkinson´s disease patients

    H. Brožová, K. Poláková, T. Gentileová, M. Fialová, M. Kubjatková, J. Rusz, M. Sap, M. Kuzma, H. Pelantová, M. Jandová, D. Funda (Prague, Czech Republic)

    Objective: The primary aim of the project was to evaluate the effect of long-term administered gluten-free diet (GFD) on motor symptoms of Parkinson's disease (PD).…
  • 2024 International Congress

    Istradefylline therapy for dystonia in Parkinson’s disease

    NAO. Kanzato, KOH. Nakachi, SAT. Mochizuki, (Okinawa, Japan)

    Objective: To clarify the basal ganglia network links between PD and Dystonia in PD (Dys-PD) co-occur, and to get the conceptually novel pharmacotherapy. Background: Dys-PD is one…
  • « Previous Page
  • 1
  • …
  • 177
  • 178
  • 179
  • 180
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley